Clinical Trial Update: Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous Urticaria [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating therapeutic equivalence of SYN008 vs Xolair in refractory chronic spontaneous urticaria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• SYN008
• Xolair (omalizumab)

Snippet

Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Conditions: Chronic Spontaneous Urticaria | Phase 3 | Status: UNKNOWN